Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer

Starting soon · Not applicable

Conditions studied: Early Stage Breast Carcinoma, Breast Cancer

In brief

This prospective study is designed to evaluate the feasibility, efficacy, and safety of risk-stratified hypofractionated radiotherapy after breast-conserving surgery in patients with early breast cancer.

Key facts

Study ID

NCT07657442

Run by

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

People needed

649

Starts

2026-06-15

Expected to finish

2032-12-31

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• ECOG performance status score of 0 to 2.
• Pathologically confirmed breast cancer, including invasive carcinoma or ductal carcinoma in situ.
• Clinical stage cT0-2N0M0.
• Underwent breast-conserving surgery.
• Negative surgical margins greater than 2 mm.

You may not qualify if…

• Regional lymph node metastasis.
• Distant metastasis.
• Bilateral breast cancer.
• Prior thoracic radiotherapy.
• Life expectancy of less than 5 years.
• Lactating or pregnant women.

Where it is running

• Cancer Hospital, Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.